Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04626 (
erbB-2
)
5,251
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Nucleolar antigen
P120
is detected in rapidly proliferating cells but not in normal resting cells or in many benign and slowly growing malignant tumors. The objective of the study was to determine whether the expression of
P120
in breast cancer correlated with histopathological or biological properties associated with prognosis. In this retrospective study, 120 primary breast tumors were analyzed for
P120
; 114 of these tumors were also stained for the
erbB-2
protein. Immunopositive staining was correlated with patient survival, nodal status, estrogen receptor levels, and number of mitoses. Sixty-nine % (83 of 120) of the tumors were positive for
P120
; 25% (28 of 114) stained positively for
erbB-2
. Of the 28
erbB-2
positive tumors 26 were also positive for the
P120
protein. Forty-six % (55 of 120) of the specimens were from patients who later died from recurrent breast cancer;
P120
was detected in 89% (49 of 55) of these specimens. In 52% of the survivors the
P120
protein was also expressed.
P120
negative tumors were highly correlative with survival (P = 0.0001); 84% (32 of 37) of patients with
P120
negative tumors survived more than 7 years without evidence of recurrent disease. Multivariate analysis showed that the worst prognosis was for patients who had tumor positive nodes and expressed
P120
(P = 0.0001); death occurred in 73% (30 of 41) of these patients. For the node negative patients who did not express
P120
, 5-year survival was 90% (19 of 21 patients); 5-year survival for the node negative patients who expressed
P120
was significantly less (67%; 28 of 42 patients). Patients with
P120
negative tumors had a good prognosis, irrespective of their nodal status. In this group, survival of node negative patients was 86% (18 of 21) and for those with positive nodes survival was 82% (13 of 16). A poor prognosis was found for patients with intense
erbB-2
stained tumors (5 of 7 patients died). Weak staining of
erbB-2
tumors (21 specimens) was not correlated with patient survival. Compared to
P120
negative tumors,
P120
positive tumors had greater numbers of mitoses (9.06 versus 6.65) and an almost 2-fold increase in the occurrence of positive nodes (one of every 4.67 versus one of every 8.81). The number of
P120
positive tumors was greater in estrogen receptor positive tumors (75%) than in estrogen negative tumors (54%).(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Prognostic significance of proliferation associated nucleolar antigen P120 in human breast carcinoma. 167 21